Rhinomed Ltd

What Rhinomed Ltd does

Rhinomed Ltd is an Australian medical technology company that develops wearable nasal technology products addressing respiratory, sleep, athletic, and diagnostic applications. Its proprietary platform leverages nasal airway physiology and is protected by a family of over 60 patents and 57 design patents globally. The company markets four core products: Rhinoswab and Rhinoswab Junior — patented self-administered nasal sampling devices for upper respiratory pathogen detection including SARS-CoV-2, influenza, and RSV, with clinical evidence of equivalent accuracy to combined nose-and-throat swabs and 98% patient comfort rates; and Mute and Turbine — consumer nasal dilators marketed respectively for snoring reduction and sports performance, each demonstrated to increase nasal airflow by up to 38%.

The company operates a dual business model. Consumer revenue is generated through direct-to-consumer e-commerce (rhinomedshop.com and regional storefronts) plus retail pharmacy distribution across more than 20,000 pharmacies worldwide including CVS in the US. B2B medical device revenue is generated through direct sales to hospitals, pathology laboratories, and government health departments, supplemented by exclusive distribution agreements — notably SureScreen Australia for lateral flow point-of-care kits across AU/NZ/Singapore/South Pacific, plus BioTrading Benelux and AntiMicrobial Technologies Group. A third revenue stream consists of licensing royalties from a 12-year exclusive agreement with Columbia Care LLC for nasal cannabinoid delivery in the US market.

The company is headquartered in Cremorne, Victoria, with a regional US office at 41 Madison Avenue, New York, and operates through a wholly-owned subsidiary, ASAP BreatheAssist Pty Ltd. FY24 unaudited revenue reached A$9.2 million, up 21% year on year. Rhinomed was removed from the official ASX list in February 2024, and in April 2025 entered into a Bid Implementation Agreement with Rhinomed Health Corporation, which has subsequently taken its stake above 50% — signaling an active change of control. Management is led by CEO Michael Johnson and Chairman Ron Dewhurst, with Associate Professor John McBain AO as Non-Executive Director.

Name

Rhinomed Ltd

Legal name

Rhinomed Limited

Website

https://rhinomed.global

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Rhinomed Ltd is an Australian medical technology company that develops wearable nasal devices — Rhinoswab and Rhinoswab Junior diagnostic swabs, plus Mute and Turbine consumer nasal dilators — serving healthcare providers, government health departments, retail pharmacy networks, and licensing partners across more than 20 countries.

Ownership category

akta.pro rank

Product category

Respiratory Medical Devices

NAICS

Toilet Preparation Manufacturing (325620)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industries

Eye, Ear & Nasal Care (HLAIADAF), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Nasal medical devices
• Respiratory diagnostics
• Wearable nasal technology
• Nasal dilator products
• Clinical sample collection

Headquarters

HQ city

Victoria Valley

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Consumer Nasal Devices Sales: Sale of Mute (anti-snoring sleep device), Turbine (sports breathing aid), and other nasal breathing products directly to consumers via e-commerce platforms and through retail pharmacy distribution.
2. Medical Device Sales (Rhinoswab): Sale of Rhinoswab and Rhinoswab Junior nasal swabs to healthcare providers, pathology laboratories, government health departments, and point-of-care testing companies. Minimum order quantity of 1000 swabs for commercial use.
3. Technology Licensing: 12-year exclusive licensing agreement with Columbia Care LLC for use of Rhinomed's nasal platform technology for delivery of cannabinoid formulations in the US market.

Pricing tiers

Go-to-market motion3 records

Distribution channels7 records

Marketing channels6 records

Core offering

Rhinomed designs, manufactures, and commercialises wearable nasal medical devices spanning respiratory diagnostics (Rhinoswab and Rhinoswab Junior nasal sampling swabs for COVID-19 and other upper respiratory pathogens), sleep and snoring management (Mute nasal dilator), and sports breathing performance (Turbine nasal dilator). Products are sold through consumer retail pharmacies and e-commerce, as well as directly to pathology labs, hospitals, and government health departments, with additional technology licensing for cannabinoid nasal drug delivery.

Product overview

Rhinomed is a wearable nasal technology company offering four main product lines. Rhinoswab and Rhinoswab Junior are nasal sampling devices for respiratory disease diagnosis - Rhinoswab is designed for adults while Rhinoswab Junior is the world's first child-friendly nasal swab for children 4+ years. Mute is a nasal dilator addressing snoring and sleep quality by increasing nasal airflow by 38%. Turbine is a sports-focused nasal dilator that enhances breathing during athletic performance by up to 38%. All products leverage Rhinomed's patented nasal technology platform protected by over 60 patents globally.

Differentiator

Problem solved

Functional benefit

Brands

• Mute: Nasal breathing aid for snoring and sleep improvement.
• Turbine
• Rhinoswab
• Rhinoswab Junior
• Pronto

Products and services

• Rhinoswab Patented comfortable, self-administered nasal swab providing high-yield sampling for COVID-19 and upper respiratory pathogens including influenza and RSV. Clinically validated as equivalent to combined nose-and-throat swab for SARS-CoV-2 detection and compatible with RT-PCR and rapid antigen testing. Sold to healthcare providers, pathology labs and government health departments with a minimum order quantity of 1,000 swabs.
• Rhinoswab Junior The world's first nasal swab designed specifically for children aged 4 years and over, with a child-friendly design that reduces anxiety around testing while providing standardised, comfortable sample collection. Validated for PCR and rapid antigen tests with 91% sensitivity and 99% specificity in detecting paediatric respiratory viruses.
• Mute Nasal dilator device designed to reduce snoring and improve sleep quality by dilating nasal passages, delivering on average 38% more airflow through the nose to reduce mouth breathing. Sold directly to consumers via e-commerce and retail pharmacies worldwide.
• Turbine Nasal dilator designed for athletes that assists with nasal obstruction and congestion during aerobic activity, delivering up to 38% more airflow to help athletes take one extra breath during track, field, bike, or workout activity. Sold directly to consumers via e-commerce and sports retail channels.

Quantifiable outcome

• Up to 38% increase in nasal airflow with Mute and Turbine devices
• +5 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core, minor and support.

• SureScreen AustraliacoreChannel Partner/ Reseller/ Distributor · 18 July 2022Exclusive supply agreement for Rhinoswab and Rhinoswab Junior products for inclusion in SureScreen's lateral flow point of care test kits. Covers Australian, New Zealand, Singapore, and South Pacific markets. First product was SARS-CoV-2 Antigen Rapid Test Cassette for children featuring Rhinoswab Junior.
• AntiMicrobial Technologies Group (AMTG)minorChannel Partner/ Reseller/ Distributor · 10 September 2021Distributor of Rhinoswab products in Western Australia.
• BioTrading Benelux BVminorChannel Partner/ Reseller/ Distributor · 10 September 2021Distributor of Rhinoswab products in Belgium, Netherlands, and Luxembourg (Benelux region).
• Columbia Care LLCcoreOEM/ Whitelabel/ Licensing Partner · 1 October 201812-year exclusive licensing agreement for Rhinomed's nasal platform technology for delivery of cannabinoid formulations in the US market. Columbia Care is the largest medical cannabis operator in the United States. Enables nasally delivered, dose-controlled cannabinoid medicines.
• Medical Device Safety Service GmbH (MDSS)supportOthersAuthorized Representative per EU Regulation 2017/745 (MDR) enabling Rhinomed's CE Mark certification and market access in Europe.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• ResMed: Global leader in sleep-disordered breathing and respiratory care devices (CPAP, masks, diagnostics). Overlaps with Rhinomed's Mute sleep technology in the broader sleep-and-snoring patient pathway, though it operates at significantly larger scale across different device categories.
• Fisher & Paykel Healthcare: New Zealand-based respiratory care and humidification device manufacturer. Adjacent peer given Rhinomed's nasal airflow and respiratory health focus (Mute, Turbine), though it serves primarily hospital and home respiratory care rather than OTC nasal dilators.
• Koninklijke Philips (Sleep & Respiratory): Global healthcare major with a sleep and respiratory portfolio (CPAP, oxygen therapy, nebulization). Comparable to Rhinomed at the broad respiratory care category level, with overlap in addressing nasal airflow and sleep-disordered breathing consumers.
• Becton, Dickinson and Company (BD): Global medical technology giant with a substantial diagnostic specimen collection and microbiology portfolio. Competes with Rhinomed's Rhinoswab across healthcare systems and pathology labs and also operates in adjacent sample preparation and respiratory testing workflows.
• Hologic: Major women's health and diagnostic company with significant molecular respiratory testing franchise (e.g., Panther system, SARS-CoV-2 assays). Indirectly comparable to Rhinomed as a downstream consumer of high-quality nasal sample collection devices.

Direct peers

• Church & Dwight (Breathe Right): Owner of the Breathe Right brand, the dominant OTC external nasal dilator strip. Directly competes with Rhinomed's Mute product in the snoring and nasal congestion consumer retail channel, including 20,000+ global pharmacy distribution.
• Copan Diagnostics: Italian-headquartered global leader in pre-analytic specimen collection, including the Copan ESwab, which is the explicit clinical benchmark against which Rhinomed's Rhinoswab is compared. Directly competes with Rhinomed in the nasal swab sample collection market.
• Puritan Medical Products: US-based manufacturer of flocked swabs and specimen collection devices, including products for COVID-19, influenza, and RSV testing. Directly competes with Rhinoswab in the diagnostic nasal swab category.

Emerging players

• Aptar Pharma: Specialist in nasal and pulmonary drug delivery systems and device components for pharmaceutical partners. Comparable to Rhinomed's nasal drug delivery platform and Columbia Care-style licensing model, with a focus on enabling third-party nasal therapeutics.
• NoseWings / Max-Air Nose Cones: Smaller OTC nasal dilator brands targeting athletes and snorers. Comparable as niche emerging players in the same consumer nasal dilator category where Rhinomed's Mute and Turbine compete.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/rhinomedceo
• LinkedInlinkedin.com/company/rhinomed-limited-australia

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rhinomed Ltd